跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/NCT02321878
NCT02321878已完成不适用

Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)

Novo Nordisk A/S1 个研究点 分布在 1 个国家目标入组 1,092 人开始时间: 2014年12月15日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
1,092
试验地点
1
主要终点
Number of AEs (adverse events)
研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This trial is conducted in Asia. The aim of this trial is to evaluate safety and effectiveness of Victoza® in patients with type 2 diabetes mellitus (T2DM) in combination with antidiabetes agents other than sulfonylurea under post-marketing normal clinical practice conditions.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者
否

入选标准

  • •Informed consent obtained before any study-related activities (Study-related activities are any procedure related to recording of data according to the protocol)
  • •Patients with T2DM (type 2 diabetes mellitus) who the physician has decided to start treatment with Victoza® in combination with insulin or OAD (oral anti-diabetes drug) other than SU (sulfonylurea)
  • •Male or female, no age limitation

排除标准

  • •Previous participation in this study or NN2211-3772 Participation is defined as informed consent obtained for this study or enrolment for NN2211-3772
  • •Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
  • •Patients who are on Victoza® or have previously been on Victoza® within 3 month before the enrolment

研究组 & 干预措施

Liraglutide

干预措施: liraglutide (Drug)

结局指标

主要结局

Number of AEs (adverse events)

时间窗: Week 0-52

次要结局

  • Number of adverse reactions (ARs)(Week 0-52)
  • Change in HbA1c (glycosylated haemoglobin)(Week 0, week 52)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

已完成
不适用
Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ryzodeg®Diabetes
NCT02821052Novo Nordisk A/S1,355
已完成
不适用
Surveillance Study of NovoRapid® for New Drug Re-examinationDiabetesDiabetes Mellitus, Type 1Diabetes Mellitus, Type 2
NCT01490112Novo Nordisk A/S1,239
已完成
不适用
A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in IndiaDiabetesDiabetes Mellitus, Type 2
NCT01212133Novo Nordisk A/S1,386
已完成
不适用
Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®Diabetes Mellitus, Type 2Diabetes Mellitus, Type 1
NCT01984372Novo Nordisk A/S6,163
已完成
不适用
NovoLet® Surveillance Study on Using Human Insulin System in IndonesiaDiabetes Mellitus, Type 1DiabetesDiabetes Mellitus, Type 2
NCT01492153Novo Nordisk A/S1,981